{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-060416","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2022-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.611305+00:00","generated_at":"2026-06-25T16:48:24.351333+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Avenue Therapeutics appoints David Jin as Interim Principal Financial Officer","bullets":["David Jin, 32, appointed Interim Principal Financial Officer effective May 11, 2022.","Jin also serves as Interim Principal Executive Officer and Chief Operating Officer.","Jin is VP of Corporate Development at Fortress Biotech; prior roles include Barings, Sorrento Therapeutics, FBR & Co, IMS Health.","No family relationships with directors or executive officers; no reportable transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-060416","json":"https://secwatch.observer/filing/0001104659-22-060416.json","markdown":"https://secwatch.observer/filing/0001104659-22-060416.md","text":"https://secwatch.observer/filing/0001104659-22-060416.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922060416/0001104659-22-060416-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922060416/tm2215290d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T16:48:24.351333+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"207fe89ec2","claim":"David Jin was appointed as Interim Principal Financial Officer at AVENUE THERAPEUTICS, INC..","evidence_excerpt":"On May 11, 2022, Avenue Therapeutics, Inc. (the “Company”) appointed David Jin as the Company’s Interim Principal Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922060416/0001104659-22-060416-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Principal Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}